BACKGROUND
Gegen qinlian decoction (GGQLD) is a form of
traditional Chinese medicine used for hundreds of years for its efficacy in treating diabetes. However, the mechanisms underlying the
therapeutic effects of GGQLD on diabetes are still not clear. We aimed to evaluate the effect of GGQLD on hepatic
insulin resistance (IR) through silent information regulator1 (
SIRT1)/forkhead box O1 (FOXO1) in an IR mouse model. MATERIAL AND METHODS A high-fat diet (HFD) mouse model was established and GGQLD was administrated by oral gavage. Metabolic parameters were detected, including
body weights,
triglyceride, fasting
glucose, fasting
insulin and HOMA-IR index,
glucose intolerance, and
insulin resistance. HE-stained sections were used to observe the histopathology of liver tissue. For in vitro study, GGQLD-medicated serum was used to treat
palmitic acid-stimulated HepG2 cells. The
glycogen synthesis and downstream
SIRT1/FOXO1 signaling pathways were examined. Specific siRNAs were used to knock down
SIRT1 in HepG2 cells. RESULTS GGQLD administration significantly decreased
body weights,
triglyceride level, fasting
glucose level, fasting
insulin level, and HOMA-IR index, and improved IR in HFD mice. GGQLD enhanced
SIRT1 expression and suppressed the expression of Ac-FOXO1 in liver tissues. Further, GGQLD-medicated serum promoted
SIRT1 upregulation and suppressed Ac-FOXO1 levels in
palmitate-stimulated HepG2 cells. GGQLD-medicated serum also increased the
protein expression of PPARĪ³ and reduced the expression of FABP4 in
palmitate-stimulated HepG2 cells. CONCLUSIONS We found that GGQLD alleviates
insulin resistance through SIRT1-dependent deacetylation of FOXO1.